Position in FATE
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$160,776
+$105,375 QoQ
Shares Held
59,547
+29.0% QoQ
Ownership
0.050%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#66
of 156 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 5%
Shared 0%
None 95%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Focus Partners Wealth holds $223,178,682 across 77 Biotechnology names. FATE ranks #48 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
128,958 | $64,057,307 | |
| 2 | CELC |
Celcuity Inc.
|
232,559 | $24,330,322 | |
| 3 | ABVX |
Abivax S.A.
|
161,874 | $21,571,329 | |
| 4 | INCY |
Incyte Corp
|
161,917 | $18,354,911 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
163,036 | $12,760,827 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
147,917 | $11,728,338 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
14,043 | $8,756,372 | |
| 8 | EXEL |
Exelixis, Inc.
|
112,673 | $6,130,537 |
All Filings in FATE
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $160,776 | 59,547 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $55,401 | 46,168 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $31,326 | 31,966 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $15,293 | 12,138 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $36,641 | 32,716 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $23,858 | 30,201 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $39,918 | 24,193 | Shares | Sole | 2025-05-20 | |
| 2024-09-30 | $82,785 | 23,653 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $78,411 | 23,906 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $173,613 | 23,653 | Shares | Sole | 2024-05-16 | |
| No filing history on record for this holder in this stock. | ||||||